Melanoma Institute Australia joins forces with Wollongong Wolves in the fight against melanoma
6 February 2017
The world’s largest melanoma-specific treatment and research facility, Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.
CEO of Melanoma Institute Australia, Carole Renouf, announced the partnership at a function in Wollongong in support of Wolves’ legend David Cervinski who is battling melanoma.
Ms Renouf said the partnership between MIA and the Wollongong Wolves would help promote sun safe behaviour amongst Wolves’ players and also spread the life-saving message to family and fans.
“It is crucial that young Australians take steps now to protect their skin from sun damage,” Ms Renouf said. “Intense, intermittent sun exposure leading to sunburn, especially before puberty, significantly increases your risk of developing melanoma in the future.
“The real tragedy of melanoma is that it is largely preventable, so we are delighted to be working with the Wollongong Wolves from the grass roots level to change behaviour and save lives.”
CEO of Wollongong Wolves Football Club Chris Papakosmas said, “Partnering with Melanoma Institute Australia is one of the most important sponsorships for our club. Following on from David Cervinski’s recent battles we thought this was a great way to raise awareness.”
One Australian dies from melanoma every six hours. Melanoma is the most common cancer affecting 15-39 year-old Australians and the leading cause of cancer death in 20-39 year-olds. The incidence of melanoma in the over 60s is also high, a legacy of sun-damage from decades ago.
As part of the partnership, Melanoma Institute Australia’s logo will feature prominently on the 2017 jerseys of all Wollongong Wolves juniors. There will also be ongoing education, sun-safety and fundraising campaigns, including the Wolves involvement in MIA’s annual Melanoma March fundraising event at Wollongong’s Stuart Park on Sunday 12 March.
“This partnership is crucial in tackling melanoma head on,” said Ms Renouf. “We are delighted to be working with the Wollongong Wolves and together help end melanoma for future generations.”
Wolves’ fans can join the fight against melanoma by participating in Melanoma March Wollongong on Sunday 12 March. To register, go to www.melanomamarch.org.au
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.